繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

DarioHealth报告第一季度业绩

2024-05-15 18:40

  • DarioHealth press release (NASDAQ:DRIO): Q1 revenues for the first quarter ended March 31, 2024, were $5.8 million, an 18.5% decrease from $7.1 million for the first quarter ended March 31, 2023, and an increase of 59% from $3.6 million for the fourth quarter of 2023.
  • Net loss was $7.2 million in the first quarter of 2024, a decrease of $5.6 million, or 44%, compared to a net loss of $12.8 million in the first quarter of 2023, and a decrease of $7.1 million, or 50%, compared to $14.3 million in the fourth quarter of 2023. 
  • EPS loss of $0.20.
  • Non-GAAP billings for the three months ended March 31, 2024, were $5.8 million, a 13% decrease from $6.7 million for the three months ended March 31, 2023. 

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。